A phase II trial with monoclonal antibody CG250 in advanced renal cell carcinoma.

被引：0
|
作者：
Varga, Z
Hegele, A
Hofmann, R
De Mulder, PD
Kruit, W
Warnaar, S
Mala, C
Ullrich, S
Huber, C
Lamers, C
Beck, J
机构：
来源：
JOURNAL OF UROLOGY | 2002年 / 167卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：192 / 193
页数：2
相关论文
共 50 条
  • [11] A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
    I Bleumer
    A Knuth
    E Oosterwijk
    R Hofmann
    Z Varga
    C Lamers
    W Kruit
    S Melchior
    C Mala
    S Ullrich
    P De Mulder
    P F A Mulders
    J Beck
    British Journal of Cancer, 2004, 90 : 985 - 990
  • [12] RADIOIMMUNOTHERAPY USING LUTETIUM-177 LABELLED MONOCLONAL ANTIBODY CG250 STABILISES PREVIOUSLY PROGRESSIVE ADVANCED RENAL CELL CARCINOMA
    Stillebroer, A. B.
    Oosterwijk, E.
    Boerman, O. C.
    Oyen, W. J. G.
    Mulders, P. F. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 230 - 230
  • [13] INTERIM ANALYSIS OF A PHASE I RADIOIMMUNOTHERAPY STUDY IN ADVANCED RENAL CELL CARCINOMA PATIENTS USING LUTETIUM-177 LABELED MONOCLONAL ANTIBODY CG250
    Stillebroer, A.
    Oosterwijk, E.
    Boerman, O. C.
    Oyen, W. J. G.
    Mulders, P. F. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 185 - 185
  • [14] Fractionated radioimmunotherapy with I-131-labeled chimeric antibody G250 (cG250) in patients with metastatic renal cell carcinoma.
    Divgi, CR
    O'Donoghue, JA
    McGagh, DA
    Motzer, RJ
    Anwar, K
    Sheikh, A
    Gonzalez, RS
    Welt, S
    Old, LJ
    Larson, SM
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 217P - 217P
  • [15] LUD01-014: Phase 1/2 study of chimeric monoclonal antibody cG250 in combination with vinblastine in patients with advanced renal cell carcinoma (ARCC).
    Al-Batran, SE
    Neumann, A
    Atmaca, A
    Ruppert, M
    Karbach, J
    Ritter, G
    Hoffman, E
    Old, L
    Knuth, A
    Jaeger, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 170S - 170S
  • [16] Chimeric monoclonal antibody CG250 (Rencarex®) as immunotherapy of renal cell carcinoma:: clinical Phase II summary and current adjuvant Phase III trial in non-metastasized RCC after nephrectomy
    Belldegrun, A
    ANNALS OF ONCOLOGY, 2005, 16 : 18 - 18
  • [17] A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients (pts) with advanced renal cell carcinoma (RCC).
    Davis, ID
    Liu, Z
    Saunders, W
    Lee, FT
    Spirkoska, V
    Hopkins, W
    Smyth, F
    Hoffman, EW
    Old, LJ
    Scott, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 177S - 177S
  • [18] Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250
    Hendrickx, Baudewijn W.
    Punt, Cees J. A.
    Boerman, Otto C.
    Postema, Ernst J.
    Oosterwijk, Egbert
    Mavridu, Agapi
    Corstens, Frans H. M.
    Oyen, Wim J. G.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2006, 21 (03) : 263 - 268
  • [19] Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody cG250
    Hendrickx, B. W.
    Punt, C. J. A.
    Boerman, O. C.
    Postema, E. J.
    Mavridu, A.
    Corstens, F. C.
    Oyen, W. J. G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S206 - S206
  • [20] Phase II trial of weekly docetaxel and capecitabine in advanced renal cell carcinoma.
    Vaishampayan, UN
    Heilbrun, LK
    Eliason, J
    Pontes, E
    Forman, J
    Cher, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 424S - 424S
12345